Comparative Pharmacology
Head-to-head clinical analysis: ALDORIL 15 versus DEMI REGROTON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALDORIL 15 versus DEMI REGROTON.
ALDORIL 15 vs DEMI-REGROTON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
DEMI-REGROTON is a fixed-dose combination of chlorothiazide (a thiazide diuretic) and reserpine (a Rauwolfia alkaloid). Chlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule, reducing sodium and water reabsorption. Reserpine depletes catecholamines (norepinephrine, dopamine, serotonin) from central and peripheral nerve endings by inhibiting vesicular monoamine transporter 2 (VMAT2), leading to reduced sympathetic outflow and vasodilation.
1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.
One tablet orally once daily, each tablet containing 25 mg chlorthalidone and 0.125 mg reserpine.
None Documented
None Documented
Terminal half-life: 12–17 hours; clinical context: steady-state achieved within 2–3 days; effect persists 12–24 hours
Terminal elimination half-life is 40-60 hours (mean 48 h), allowing once-daily dosing; steady state reached in 5-7 days
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
Renal: 70% as unchanged drug; biliary/fecal: 30% as metabolites
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination